FDA grants approval of Besponsa for acute lymphoblastic leukaemia
The FDA has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia...
List view / Grid view
The FDA has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia...
GlobalData latest report states that the major drivers of this growth include the projected launch of prophylactic options for the prevention of Clostridium difficile infections...
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
P is for Psoriasis - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
30 November 2016 | By Niamh Louise Marriott, Digital Editor
M is for MRSA - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
24 November 2016 | By Niamh Louise Marriott, Digital Content Producer
I is for Immuno-oncology - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in this cancer research...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
2 August 2016 | By GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...
1 August 2016 | By GlobalData
Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report...
6 July 2016 | By Victoria White, Digital Content Producer
The type 2 diabetes market will see companies prioritisng competitive pricing in order to offset the impact of patent expiries, says GlobalData...
29 June 2016 | By Victoria White, Digital Content Producer
GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
27 June 2016 | By Victoria White, Digital Content Producer
Merck’s acquisition of Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing IPF market, according to GlobalData...
27 June 2016 | By Victoria White, Digital Content Producer
While a Brexit undoubtedly creates significant issues for the UK pharma industry, opportunities remain for the sector to thrive, according to GlobalData...
23 June 2016 | By Victoria White, Digital Content Producer
The company says for the healthcare industry to thrive in the event of the UK leaving the EU, the country would need to adopt a uniquely British approach...